Cost-Effectiveness Analysis of Anlotinib Plus Penpulimab vs. Sorafenib for Liver Cancer

A Chinese healthcare system perspective cost-effectiveness analysis of first-line treatments for unresectable hepatocellular carcinoma. The dataset, authored by Gengliang Bai and last updated in May 2026, contains the results of a partitioned survival model comparing anlotinib plus penpulimab to sorafenib monotherapy. It includes base-case results, sensitivity analyses, and scenario analyses based on data from the APOLLO phase III clinical trial.

Use Cases

• Evaluate the incremental cost-effectiveness ratio (ICER) of combination cancer therapy based on the reported QALY gains and incremental costs.
• Conduct sensitivity analysis on pharmacoeconomic models based on the utility values and drug price parameters identified in the study.
• Assess the impact of drug price reductions on treatment cost-effectiveness based on the scenario analysis results.
• Compare first-line treatment strategies for unresectable hepatocellular carcinoma based on the clinical and economic outcomes modeled.

Strengths

• Model results are based on the phase III APOLLO clinical trial (NCT04344158).
• Analysis follows the China Guidelines for Pharmacoeconomic Evaluations 2025.
• Includes one-way and scenario sensitivity analyses to test model robustness.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The 814.7 KB file size suggests a limited scope, likely containing the analysis document rather than extensive raw data.

Provenance

Source

Gengliang Bai via figshare

Collection Method

Partitioned survival model using clinical data from the APOLLO trial and cost/utility data from local databases and literature.

Time Range

Patient lifetime horizon.

Freshness

Last updated 2026-05-21 04:37:09; freshness should be verified.

Geography

Perspective of the Chinese healthcare system.